Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker-Reference-Cited by-同舟云学术

Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker

Published:2021-02-04 Issue:7 Volume:7 Page:1901-1922
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Abdelhameed Ahmed¹²,Feng Mei³,Joice April C.¹,Zywot Emilia M.¹,Jin Yiru³,La Rosa Chris¹,Liao Xiaoping¹,Meeds Heidi L.¹,Kim Yena¹,Li Junan⁴,McElroy Craig A.¹,Wang Michael Zhuo³^ORCID,Werbovetz Karl A.¹^ORCID

Affiliation:

1. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States

2. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt

3. Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047, United States

4. College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States

Funder

National Institute of Allergy and Infectious Diseases

Neglected Disease Drug Discovery Fund of the Ohio State University College of Pharmacy

Office of the Assistant Secretary of Defense for Health Affairs under the Peer Reviewed Medical Research Program

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.0c00855

Reference66 articles.

1. World Health Organization (accessed 2020-10-28) Leishmaniasis, www.who.int/health-topics/leishmaniasis#tab=tab_1.

2. An update on pharmacotherapy for leishmaniasis

3. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies

4. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia

5. Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors;Bioorganic & Medicinal Chemistry;2024-09

2. Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma;ACS Infectious Diseases;2024-04-26

3. Synthetic product-based approach toward potential antileishmanial drug development;European Journal of Medicinal Chemistry;2024-01

4. Synthesis and Biophysical and Biological Studies of N-Phenylbenzamide Derivatives Targeting Kinetoplastid Parasites;Journal of Medicinal Chemistry;2023-09-20

5. A combined 2-D and 3-D QSAR modeling, molecular docking study, design, and pharmacokinetic profiling of some arylimidamide-azole hybrids as superior L. donovani inhibitors;Bulletin of the National Research Centre;2022-06-29